Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer
| dc.contributor.author | Peeters, M | |
| dc.contributor.author | Oliner, K | |
| dc.contributor.author | Price, T | |
| dc.contributor.author | Cervantes, A | |
| dc.contributor.author | Sobrero, A | |
| dc.contributor.author | Ducreux, M | |
| dc.contributor.author | Hotko, Y | |
| dc.contributor.author | André, T | |
| dc.contributor.author | Chan, E | |
| dc.contributor.author | Lordick, F | |
| dc.contributor.author | Punt, C | |
| dc.contributor.author | Strickland, A | |
| dc.contributor.author | Wilson, Gregory | |
| dc.contributor.author | Ciuleanu, T | |
| dc.contributor.author | Roman, L | |
| dc.contributor.author | Van Cutsem, E | |
| dc.contributor.author | He, P | |
| dc.contributor.author | Yu, H | |
| dc.contributor.author | Koukakis, R | |
| dc.contributor.author | Terwey, J | |
| dc.contributor.author | Jung, A | |
| dc.contributor.author | Sidhu, R | |
| dc.contributor.author | Patterson, S | |
| dc.date.accessioned | 2016-03-03T14:45:11Z | en |
| dc.date.available | 2016-03-03T14:45:11Z | en |
| dc.date.issued | 2015-12-15 | en |
| dc.identifier.citation | Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. 2015, 21 (24):5469-79 Clin Cancer Res | en |
| dc.identifier.issn | 1078-0432 | en |
| dc.identifier.pmid | 26341920 | en |
| dc.identifier.doi | 10.1158/1078-0432.CCR-15-0526 | en |
| dc.identifier.uri | http://hdl.handle.net/10541/600544 | en |
| dc.description.abstract | We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183). | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Clinical cancer research : an official journal of the American Association for Cancer Research | en |
| dc.title | Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer | en |
| dc.type | Article | en |
| dc.contributor.department | Antwerp University Hospital and University of Antwerp, Edegem, Belgium. | en |
| dc.identifier.journal | Clinical Cancer Research | en |
| html.description.abstract | We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183). |